T. Rowe Price Associates
TEVA icon

T. Rowe Price Associates’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

T. Rowe Price Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-22,700
Closed -$350K – 2564
2018
Q4 		$350K Hold
22,700
– – ﹤0.01% 2222
2018
Q3 		$489K Hold
22,700
– – ﹤0.01% 2160
2018
Q2 		$552K Hold
22,700
– – ﹤0.01% 2090
2018
Q1 		$388K Buy
+22,700
New +$443K ﹤0.01% 2183

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

T. Rowe Price Associates's TEVA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Teva Pharmaceutical Industries Limited (TEVA) stake by 165% in Q2 2026, buying an estimated $34.8M and bringing the position to 1,679,152 shares worth $56.9M. The position accounts for 0.01% of the portfolio, ranked #855.

T. Rowe Price Associates first reported a position in TEVA in Q2 2013 and has held it in 48 quarters since. The position peaked at $462M in Q1 2015. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • T. Rowe Price Associates held 1,679,152 shares of Teva Pharmaceutical Industries Limited worth $56.9M as of Q2 2026.
  • T. Rowe Price Associates bought 1,045,016 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $34.8M.
  • Teva Pharmaceutical Industries Limited made up 0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #855 holding.
  • T. Rowe Price Associates first reported a position in Teva Pharmaceutical Industries Limited in Q2 2013 and has held it in 48 quarters since.
  • T. Rowe Price Associates's Teva Pharmaceutical Industries Limited position peaked at $462M in Q1 2015.
  • 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.